- Home
- GMM vs CRDL Comparison
GMM vs CRDL Comparison
Compare GMM & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMM
- CRDL
- Stock Information
- Founded
- GMM 2017
- CRDL 2017
- Country
- GMM China
- CRDL Canada
- Employees
- GMM N/A
- CRDL N/A
- Industry
- GMM
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GMM
- CRDL Health Care
- Exchange
- GMM Nasdaq
- CRDL Nasdaq
- Market Cap
- GMM 70.8M
- CRDL 80.1M
- IPO Year
- GMM 2023
- CRDL N/A
- Fundamental
- Price
- GMM $2.79
- CRDL $1.27
- Analyst Decision
- GMM
- CRDL Strong Buy
- Analyst Count
- GMM 0
- CRDL 3
- Target Price
- GMM N/A
- CRDL $9.00
- AVG Volume (30 Days)
- GMM 25.2K
- CRDL 156.5K
- Earning Date
- GMM 06-10-2025
- CRDL 05-14-2025
- Dividend Yield
- GMM N/A
- CRDL N/A
- EPS Growth
- GMM 62.17
- CRDL N/A
- EPS
- GMM 6.37
- CRDL N/A
- Revenue
- GMM $41,360,953.00
- CRDL N/A
- Revenue This Year
- GMM N/A
- CRDL N/A
- Revenue Next Year
- GMM N/A
- CRDL N/A
- P/E Ratio
- GMM $0.44
- CRDL N/A
- Revenue Growth
- GMM 53.82
- CRDL N/A
- 52 Week Low
- GMM $1.69
- CRDL $0.77
- 52 Week High
- GMM $15.60
- CRDL $3.12
- Technical
- Relative Strength Index (RSI)
- GMM 51.23
- CRDL 59.43
- Support Level
- GMM $2.64
- CRDL $1.19
- Resistance Level
- GMM $2.99
- CRDL $1.31
- Average True Range (ATR)
- GMM 0.31
- CRDL 0.07
- MACD
- GMM 0.02
- CRDL 0.01
- Stochastic Oscillator
- GMM 51.72
- CRDL 66.91
About GMM Global Mofy Metaverse Limited
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.